Drug recall · August 25, 2021
DAUNOrubicin Hydrochloride Injection 20 mg/4mL recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
DAUNOrubicin Hydrochloride Injection 20 mg/4mL, 4mL Single Dose vials, 10 in 1 carton, Rx only, Teva Parenteral Medicines, Inc. Irvine, CA 92618 Vial NDC# 0703-5233-11, Carton NDC # 0703-5233-13
- Lots / codes
Lot #: 31329250B, exp. date 08/2022
- Quantity
- 1,351 vials
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Product was distributed Nationwide, including Puerto Rico.
- Initiated
- July 29, 2021 · Voluntary: Firm initiated
- Classified
- August 16, 2021
- Reported
- August 25, 2021
- Ended
- June 4, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Daunorubicin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.